(±)-Bay K 8644 (Synonyms: SQ 28,873) |
| Catalog No.GC15015 |
(±)-Bay K 8644 is a dihydropyridine compound that acts as a specific agonist of L-type calcium channels, with an EC₅₀ value of 17.3nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 71145-03-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(±)-Bay K 8644 is a dihydropyridine compound that acts as a specific agonist of L-type calcium channels, with an EC₅₀ value of 17.3nM[1]. (±)-Bay K 8644 promotes calcium influx into cells by increasing the open time of sarcolemmal calcium channels[2]. (±)-Bay K 8644 is widely used to study the role of L-type calcium channels in cardiovascular function, neurotransmission, and cellular signal transduction mechanisms[3]. (±)-Bay K 8644 has been shown to improve hypotension and regulate heart rate[4].
In vitro, treatment of human liver cancer HepG2 cells with (±)-Bay K 8644 (0.1–100nM) for 3–5 days significantly promoted colony formation and cell proliferation[5]. Under partial depolarization conditions induced by 25mM K⁺, a 5-minute treatment of PC12 cells with (±)-Bay K 8644 (10nM–10μM) enhanced the release of [³H]norepinephrine by 5-fold through calcium channel activation, an effect that was calcium-dependent[6].
In vivo, a single intraperitoneal injection of (±)-Bay K 8644 (1mg/kg) administered 1 hour before testing in an LPS-induced depression model in mice significantly improved depressive-like behaviors, reducing immobility time and increasing activity time[7]. In female Wistar rats, a single intraperitoneal injection of (±)-Bay K 8644 (3–5mg/kg) induced a reversible convulsion-like syndrome within 15 minutes[8].
References:
[1] Bechem M, Schramm M. Calcium-agonists. J Mol Cell Cardiol. 1987 May;19 Suppl 2:63-75.
[2] Wu L, Wang R, Karpinski E, et al. Bay K-8644 in different solvents acts as a transient calcium channel antagonist and a long-lasting calcium channel agonist. J Pharmacol Exp Ther. 1992 Mar;260(3):966-73.
[3] Baydoun AR, Markham A, Morgan RM, et al. Bay K 8644, modifier of calcium transport and energy metabolism in rat heart mitochondria: a new intracellular site of action. Br J Pharmacol. 1990 Sep;101(1):15-20.
[4] Barrús MT, Reviriego J, Marín J. Effect of Ca2+ agonist Bay K 8644 in human placental arteries. Gen Pharmacol. 1995 Sep;26(5):989-96.
[5] Yamaguchi M, Murata T, Ramos JW. The calcium channel agonist Bay K 8644 promotes the growth of human liver cancer HepG2 cells in vitro: suppression with overexpressed regucalcin. Mol Cell Biochem. 2020 Sep;472(1-2):173-185.
[6] Albus U, Habermann E, Ferry DR, et al. Novel 1,4-dihydropyridine (Bay K 8644) facilitates calcium-dependent [3H]noradrenaline release from PC 12 cells. J Neurochem. 1984 Apr;42(4):1186-9.
[7] He E, Ma R, Qu S, et al. L-methionine and the L-type Ca2+ channel agonist BAY K 8644 collaboratively contribute to the reduction of depressive-like behavior in mice. Front Neural Circuits. 2024 Aug 29;18:1435507.
[8] Petersen EN. Bay K 8644 induces a reversible spasticity-like syndrome in rats. Eur J Pharmacol. 1986 Nov 4;130(3):323-6.
| Cell experiment [1]: | |
Cell lines | HepG2 cells (human liver cancer cell line) |
Preparation Method | HepG2 cells were maintained in Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100μg/ml penicillin, and 100μg/ml streptomycin at 37°C, 5% CO₂. Cells were treated with (±)-Bay K 8644 at various concentrations (0.1-100nM) for 1-5 days. |
Reaction Conditions | 0.1-100nM; 1-5 days |
Applications | (±)-Bay K 8644 (0.1-10nM) significantly promoted colony formation and cell proliferation in HepG2 cells, while higher concentrations (25-100nM) stimulated caspase-3-dependent apoptotic cell death. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Mice received intraperitoneal injections of LPS (1mg/kg) for 7 consecutive days to induce a depression-like model. For intervention, mice were administered (±)-Bay K 8644 (1mg/kg; i.p.) 1 hour before behavioral tests. In combination therapy groups, mice were fed with L-methionine chow (19.5mg/kg) for 7 consecutive days alongside LPS injections. |
Dosage form | 1mg/kg; i.p. |
Applications | (±)-Bay K 8644 administration partially ameliorated LPS-induced depression-like behaviors, reducing immobility time in the forced swim test and increasing central zone activity in the open field test. |
References: | |
| Cas No. | 71145-03-4 | SDF | |
| Synonyms | SQ 28,873 | ||
| Chemical Name | methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate | ||
| Canonical SMILES | CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC | ||
| Formula | C16H15F3N2O4 | M.Wt | 356.3 |
| Solubility | 50mg/mL in DMSO, 50mg/mL in DMF, 50mg/mL in ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8066 mL | 14.0331 mL | 28.0662 mL |
| 5 mM | 561.3 μL | 2.8066 mL | 5.6132 mL |
| 10 mM | 280.7 μL | 1.4033 mL | 2.8066 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *